Meeting NewsVideo

VIDEO: National Liver Conference covers new, underused therapies for liver disease

SAN ANTONIO — In this exclusive video from the National Liver Conference 2019, Stephen A. Harrison, MD, medical director of Pinnacle Clinical Research in San Antonio, provides an overview of the topics discussed at the meeting ranging from nonalcoholic steatohepatitis to hepatitis B to liver cancer.

“We started out with talking about NASH. The prevalence of this disease is increasing,” Harrison told Healio Gastroenterology and Liver Disease. “We also learned that there are a lot of new therapies coming. In fact, the first FDA-approved therapy for NASH should likely come in [the second quarter] of 2020 with obeticholic acid ... along with other phase 3 [studies] that are wrapping up.”

In his overview, Harrison also covers novel therapies for coagulation disorders in cirrhosis and autoimmune liver disease, and endoscopic management of liver disease patients including endoscopic stitching for obesity management and duodenal ablative therapy to improve glycemic control.

Disclosure: Harrison reports he is a consultant for 3VBio, Akero, Albereo, Axcella, Blade Therapeutics, Bristol-Myers Squibb, Cirius, Civi, CLDF, ConSynance, ContraVir, Corcept, CymaBay, Echosens, Galectin, Galmed, Gilead, HighTide, HistoIndex, Innovate, Intercept, IQVIA, Lipocine, Madrigal, Medpace, Metacrine, NGM, Novartis, Novo Nordisk, Perspectum, Pfizer, Poxel, PPD, Prometheus, Prometic and Terns; is on the speakers bureau with Alexion; and has received research support from Allergan, Axcella, Cirius, Conatus, CymaBay, Galectin, Galmed, Genfit, Gilead, HighTide, Immuron, Intercept, Madrigal, NGM, Novartis, Novo Nordisk, Pfizer, Second Genome and Tobira.

SAN ANTONIO — In this exclusive video from the National Liver Conference 2019, Stephen A. Harrison, MD, medical director of Pinnacle Clinical Research in San Antonio, provides an overview of the topics discussed at the meeting ranging from nonalcoholic steatohepatitis to hepatitis B to liver cancer.

“We started out with talking about NASH. The prevalence of this disease is increasing,” Harrison told Healio Gastroenterology and Liver Disease. “We also learned that there are a lot of new therapies coming. In fact, the first FDA-approved therapy for NASH should likely come in [the second quarter] of 2020 with obeticholic acid ... along with other phase 3 [studies] that are wrapping up.”

In his overview, Harrison also covers novel therapies for coagulation disorders in cirrhosis and autoimmune liver disease, and endoscopic management of liver disease patients including endoscopic stitching for obesity management and duodenal ablative therapy to improve glycemic control.

Disclosure: Harrison reports he is a consultant for 3VBio, Akero, Albereo, Axcella, Blade Therapeutics, Bristol-Myers Squibb, Cirius, Civi, CLDF, ConSynance, ContraVir, Corcept, CymaBay, Echosens, Galectin, Galmed, Gilead, HighTide, HistoIndex, Innovate, Intercept, IQVIA, Lipocine, Madrigal, Medpace, Metacrine, NGM, Novartis, Novo Nordisk, Perspectum, Pfizer, Poxel, PPD, Prometheus, Prometic and Terns; is on the speakers bureau with Alexion; and has received research support from Allergan, Axcella, Cirius, Conatus, CymaBay, Galectin, Galmed, Genfit, Gilead, HighTide, Immuron, Intercept, Madrigal, NGM, Novartis, Novo Nordisk, Pfizer, Second Genome and Tobira.

    See more from National Liver Conference